Hematology (BE: haematology) is the branch of internal medicine and pediatrics that is concerned with blood, the blood-forming organs and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

Blood diseases affect the production of blood and its components, such as blood cells, hemoglobin, blood proteins, the mechanism of coagulation, etc.

Hematologists

---

Medical doctors who work in hematology are known as hematologists. Their routine work may range from the management of the hematology laboratory, work at the microscope viewing blood films and bone marrow slides, interpretation of various hematology test results, care of in-patients and care of out-patients.

More on [ Hematology ]

All Hematology-Oncology Jobs

Permanent Hematology-Oncology Job in Short Drive from Indianapolis Indiana with Enterprise Medical Service
Hospital in southern Indiana is seeking a HEM/ONC to add to their staff. The hospital currently has 2 oncologist from other cities coming to their hospital. The community as well as the hospital would
Permanent Hematology-Oncology Job in Southwest Kentucky Kentucky with Enterprise Medical Service
Join an established physician owned MSG. This group has 65 physicians and has been established for 70 years. They currently have 3 oncologists and are looking to add another to put in their satellite
Permanent Hematology-Oncology Job in Med or Hem/Onc needed in outskirts of St. Louis Missouri with Enterprise Medical Service
Join a very dynamic, state of the art practice opportunity. Currently have 64 providers in this MSG and 85% of the physicians are over 100% in yearly earnings based on MGMA standards. Brand new Cancer

Hematological Oncology

New antimicrobial agents for the treatment of bacterial infections in cancer patients
Kenneth V. I. Rolston Wed, 01 Jul 2009 01:53:00 -0000
Patients with cancer develop serious bacterial infections often, especially during periods of severe and prolonged neutropenia. Antibiotic usage for the prevention and treatment of bacterial infections in these high-risk patients leads to selection pressures resulting in the emergence and spread of resistant organisms. Many organisms acquire several resistance mechanisms, making them multi-drug-resistant (MDR) (defined as resistance to three or more different classes of antibiotics). These infections are associated with increased morbidity, mortality and costs. The development of novel antimicrobial agents with activity against pathogens that have become resistant to currently available agents is one strategy for combating resistant organisms. Several novel agents have either recently been approved, or are in various stages of development and are discussed in detail. It is unlikely that these agents will have a major impact on reducing the development and spread of MDR organisms. Consequently, the judicious use of currently available agents referred to as Antimicrobial Stewardship, and the development of and adherence to appropriate Infection Control policies and procedures are vital components in the management of these high-risk patients. Copyright © 2009 John Wiley & Sons, Ltd.
How would I manage a sample submitted for flow cytometry analysis for suspicious chronic lymphocytic leukaemia
Pietro Bulian, Giovanni Del Poeta, Valter Gattei Wed, 01 Jul 2009 01:55:00 -0000
Samples submitted for a suspect of chronic lymphocytic leukemia are the most frequently observed in flow cytometry laboratories. These cases require not only a precise and prompt diagnosis but also an evaluation on the possibility of performing additional prognostic tests. We will propose two sequential flow cytometry panels and a personal opinion on how to manage these samples for both diagnostic and prognostic assessment, taking into account the published guidelines and recommendations. Copyright © 2009 John Wiley & Sons, Ltd.
Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy
Gunhild Keller, Ute Brassat, Melanie Braig, Denise Heim, Henning Wege, Tim H. Brümmendorf Wed, 01 Jul 2009 01:56:00 -0000
Telomeres are specialized structures localized at the end of human chromosomes. Due to the end replication problem, each cell division results in a loss of telomeric repeats in normal somatic cells. In germ line and stem cells, the multicomponent enzyme telomerase maintains the length of telomere repeats. However, elevated telomerase activity has also been reported in the majority of solid tumours as well as in acute and chronic leukaemia. Chronic myeloid leukaemia (CML) serves as a model disease to study telomere biology in clonal myeloproliferative disorders. In CML, telomere shortening correlates with disease stage, duration of chronic phase (CP), prognosis measured by the Hasford risk score and the response to disease-modifying therapeutics such as the tyrosine kinase inhibitor Imatinib. In addition, telomerase activity (TA) is already increased in CP CML and further upregulated with disease progression to accelerated phase and blast crisis (BC). Furthermore, a correlation of TA with increased genetic instability as well as a shorter survival of the patients has been reported. Here, we review the current state of knowledge of the role of telomere and telomerase biology in CML and discuss the possible impact of novel treatment approaches. Copyright © 2009 John Wiley & Sons, Ltd.

Annals of Hematology

Thrombocytopenia as first manifestation of splenic angiosarcoma
Wed, 01 Jul 2009 06:13:18 -0000
Thrombocytopenia as first manifestation of splenic angiosarcoma Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0778-7Authors Simon Raffel, Charité Campus Virchow Klinikum Department of Hematology and Oncology Augustenburger Platz 1 13353 Berlin GermanyBert Hildebrandt, Charité Campus Virchow Klinikum Department of Hematology and Oncology Augustenburger Platz 1 13353 Berlin GermanyChristian Grieser, Charité Campus Virchow Klinikum Department of Radiology Augustenburger Platz 1 13353 Berlin GermanyStefan Pahl, Charité Campus Mitte Institute of Pathology Charitéplatz 1 10117 Berlin GermanyIsrid Sturm, Charité Campus Virchow Klinikum Department of Hematology and Oncology Augustenburger Platz 1 13353 Berlin Germany Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555
Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin
Tue, 30 Jun 2009 15:40:17 -0000
Abstract  Hematological abnormalities including neutropenia, anemia, and thrombocytopenia are commonly seen in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. The aim of this study was to identify factors which would help to predict the development of hematological abnormalities in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. During a 4-year period, all patients with chronic hepatitis C started on treatment with pegylated interferon and ribavirin were identified. Patients were defined as having hematological abnormalities if they had the presence of either anemia, neutropenia, thrombocytopenia, or a combination of the above during treatment with pegylated interferon and ribavirin. A total of 136 patients with chronic hepatitis C were included in this study. Fifty-two (38.2%) of the patients developed significant hematological abnormalities during treatment with pegylated interferon and ribavirin with 28 (20.6%), 30 (22.1%), and 11 (8.1%) developed neutropenia, anemia, and thrombocytopenia, respectively. Genotype 1, history of hypertension, low baseline platelet count, low baseline hemoglobin, as well as a raised creatinine were significant factors associated with the development of hematological abnormalities. Significant hematological abnormalities are commonly present in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. This study identifies pretreatment parameters that may help identify high-risk patients who are more likely to develop hematological abnormalities during treatment for chronic hepatitis C. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0774-yAuthors Jagdish S. Nachnani, University of Missouri Kansas City School of Medicine Division of Gastroenterology 2301 Holmes Street Kansas City MO 64108 USAGowtham A. Rao, VA Medical Center Kansas City Division of Gastroenterology Kansas City MO 64108 USADeepti Bulchandani, VA Medical Center Kansas City Division of Gastroenterology Kansas City MO 64108 USAPrashant K. Pandya, VA Medical Center Kansas City Division of Gastroenterology Kansas City MO 64108 USALaura M. Alba, University of Missouri Kansas City School of Medicine Division of Gastroenterology 2301 Holmes Street Kansas City MO 64108 USA Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555
Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough?
Mon, 29 Jun 2009 09:59:28 -0000
Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough? Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0775-xAuthors Donat Dürr, Stadtspital Triemli Medical Oncology Birmensdorferstrasse 497 CH-8063 Zurich SwitzerlandRaffaele Daniele Siciliano, Stadtspital Triemli Medical Oncology Birmensdorferstrasse 497 CH-8063 Zurich SwitzerlandYvonne Hummel, Stadtspital Triemli Medical Oncology Birmensdorferstrasse 497 CH-8063 Zurich SwitzerlandAlix O’Meara, Stadtspital Triemli Medical Oncology Birmensdorferstrasse 497 CH-8063 Zurich SwitzerlandAnita Hirschi, Stadtspital Triemli Medical Oncology Birmensdorferstrasse 497 CH-8063 Zurich SwitzerlandRoger Burkhard, Stadtspital Triemli Medical Oncology Birmensdorferstrasse 497 CH-8063 Zurich SwitzerlandHanspeter Honegger, Stadtspital Triemli Medical Oncology Birmensdorferstrasse 497 CH-8063 Zurich Switzerland Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555

American Journal of Hematology

Iron overload and chronically transfused patients: Numbers, scales, and clinical research
Francesco Callea Mon, 08 Jun 2009 13:41:00 -0000
No abstract.
Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo
Liang Zhang, Zhengzi Qian, Zhen Cai, Luhong Sun, Huaqing Wang, J. Blake Bartlett, Qing Yi, Michael Wang Mon, 08 Jun 2009 13:41:00 -0000
Rituximab (RTX), a chimeric anti-CD20 antibody, is associated with direct induction of apoptosis and antibody-dependent cell-mediated cytotoxicity (ADCC) with clinical efficacy in mantle cell lymphoma (MCL). Lenalidomide (LEN), a novel immunomodulatory agent, sensitizes tumor cells and enhances ADCC. Our study attempted to elucidate the mechanism of LEN-enhanced RTX-mediated cytotoxicity of MCL cells. We found that LEN and RTX induced growth inhibition of both cultured and fresh primary MCL cells. LEN enhanced RTX-induced apoptosis via upregulating phosphorylation of c-Jun N-terminal protein kinases (JNK), Bcl-2, Bad; increasing release of cytochrome-c; enhancing activation of caspase-3, -8, -9 and cleavage of PARP. Meanwhile, LEN activated NK cells and increased CD16 expression on CD56lowCD16+ NK cells. Whole PBMCs but not NK cell-depleted PBMCs treated with LEN augmented 30% of RTX-dependent cytotoxicity. Daily treatment with LEN increased NK cells by 10-folds in SCID mice, and combination of LEN and RTX decreased tumor burden and prolonged survival of MCL-bearing SCID mice. Taken together, our study demonstrates that LEN plus RTX provides a synergistically therapeutic effect on MCL cells by enhancing apoptosis and RTX-dependent NK cell-mediated cytotoxicity and may be an optimal combination in the clinical trial of relapsed or refractory MCL. Am. J. Hematol. 2009. © 2009 Wiley-Liss, Inc.
The role of antiphospholipid antibodies toward the protein C/protein S system in venous thromboembolic disease
Valeria Rossetto, Luca Spiezia, Francesca Franz, Laura Salmaso, Laura Visonà Dalla Pozza, Sabrina Gavasso, Paolo Simioni Mon, 08 Jun 2009 13:41:00 -0000
No abstract.

Pediatric Hematology and Oncology: Articles recently published in

CLINICAL PROFILE AND HOME MANAGEMENT OF SICKLE CELL-RELATED PAIN: The Enugu (Nigeria) Experience
Ocheni, SundayEmodi, Ifeoma J.Ikefuna, Anthony N. Wed, 01 Jul 2009 00:00:00 -0000

THE BENEFIT OF ATG IN IMMUNOSUPPRESSIVE THERAPY OF CHILDREN WITH MODERATE APLASTIC ANEMIA
Xie, XiaotianKuang, HanqinLin, JieliangQiao, XiaohongShi, WeiWang, YaopingJiang, ShayiShao, Yuexia Wed, 01 Jul 2009 00:00:00 -0000

RHABDOMYOSARCOMA OF THE EXTREMITIES: A Focus on Tumors Arising in the Hand and Foot
Ferrari, AndreaMorosi, CarloFavini, FrancescaMeazza, CristinaCasanova, MichelaFiore, Marco Wed, 01 Jul 2009 00:00:00 -0000


Subscribe to Hematology RSS feed